Samarth Kulkarni compensation by year
CRISPR Therapeutics Summary Compensation Table · all 10 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $352,046 | $404,650 | $514,583 | $550,200 | $625,000 | $670,000 | $700,000 | $724,500 | $746,235 | $768,622 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $506,406 | $0 | $8,775,600 | $1,585,785 | $4,819,680 | $15,211,120 | $4,435,690 | $25,344,025 | $3,474,900 |
| Option awards | $822,706 | $5,816,201 | $8,841,073 | $6,495,579 | $6,343,596 | $10,954,947 | $4,213,239 | $6,531,705 | $6,436,600 | $2,768,862 |
| Non-equity incentive | $135,360 | $196,264 | $362,250 | $438,785 | $543,750 | $587,925 | $597,800 | $618,723 | $637,285 | $659,093 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $1,052 | $10,744 | $9,625 | $5,568 | $7,125 | $4,463 | $12,200 | $11,578 | $11,481 | $7,000 |
| Total | $1,311,164 | $6,934,265 | $9,727,532 | $16,265,732 | $9,105,256 | $17,037,015 | $20,734,359 | $12,322,196 | $33,175,626 | $7,678,477 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRISPR Therapeutics AG DEF 14A filed April 21, 2026, accession 0001193125-26-165158, and prior-year filings.
How this page was built: the CRISPR Therapeutics AG filed document, accession 0001193125-26-165158. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 300,000 | $15,732,000 | — |
| RSU | 82,500 | $4,326,300 | — |
| RSU | 59,062 | $3,097,211 | — |
| RSU | 38,500 | $2,018,940 | — |
| RSU | 13,250 | $694,830 | — |
| RSU | 8,333 | $436,983 | — |
| Option | 4,792 | — | $58.29 |
| Option | 89,375 | — | $42.12 |
| Option | 58,750 | — | $43.22 |
| Option | 24,063 | — | $44.31 |
| Option | 59,063 | — | $72.94 |
| Option | 38,959 | — | $49.00 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CRISPR Therapeutics AG's FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 13 award rows shown.
Insider transactions since the last proxy
8 Form 4 lines since the FY2025 proxy (filed April 21, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-26 | Grant or award derivative | — | 28,750 | $0.00 | 28,750 |
| 2026-10-26 | Grant or award derivative | — | 57,500 | $0.00 | 57,500 |
| 2026-10-19 | Sale | — | 47,837 | $49.78 | 311,899 |
| 2026-10-16 | Exercise or conversion derivative | — | 100,000 | — | 200,000 |
| 2026-10-16 | Exercise or conversion | — | 100,000 | — | 359,736 |
| 2026-10-14 | Sale | — | 4,098 | $49.26 | 259,736 |
| 2026-10-13 | Exercise or conversion derivative | — | 8,333 | — | 0 |
| 2026-10-13 | Exercise or conversion | — | 8,333 | — | 263,834 |
The 8 most recent of 8 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
CRISPR Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Samarth Kulkarni · this page | Chairman and Chief Executive Officer | $7,678,477 |
| Naimish Patel | Chief Medical Officer | $4,309,317 |
| Julianne Bruno | Former Chief Operating Officer | $3,657,660 |
| Raju Prasad | Chief Financial Officer | $3,586,594 |
| James Kasinger | General Counsel and Secretary | $2,861,814 |
Board service
CRISPR Therapeutics board · FY2021–FY2025How this board is paid
Company policy: CRISPR Therapeutics pays directors a $50,000 cash retainer and $285,740 in Options. As stated in CRISPR Therapeutics's FY2025 proxy.
The full CRISPR Therapeutics compensation record
free company briefThis page is one person within CRISPR Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the CRISPR Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order CRISPR Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRISPR Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.